



Epicore BioNetworks Inc.

NEWS RELEASE
Date: 15 March 2017
FOR IMMEDIATE RELEASE

Epicore BioNetworks Inc. Reports New Product Offering

Eastampton, NJ – Epicore BioNetworks Inc. (TSXV EBN) reported closing a new arrangement that expands Epicore's line and delivers to shrimp hatcheries an alternative to the challenging practice of growing live algae.

Larval shrimp require a varied diet to achieve optimum growth. In addition to compound feeds like Epicore's EPIFEED[®] and EPIBAL[®] products, they require live Artemia and algae. Most shrimp hatcheries possess a large amount of competence when it comes to growing algae on site. But algae crashes do happen. When they do, what is "plan B"? Now Epicore has that answer.

Epicore has recently negotiated an arrangement with Reed Mariculture Inc. to sell a special fresh algal concentrate specially developed for hatchery shrimp rearing. Reed is the largest producer in the world of marine algae concentrates and has been in business over 20 years. Their INSTANT ALGAE[®] products are used around the world in fish hatcheries and other applications. Their products are whole cell, whole food microalgae that offer hatcheries a clean, convenient, long shelf-life feed to replace or supplement live algae.

Reed and Epicore have collaborated for two years to develop an algae mixture that will replace or supplement all the live algae now grown in shrimp hatcheries. Epicore is the exclusive distributor to the shrimp industry for this new product. Epicore is launching the product under the name EPI-ALGAE[™]. EPI-ALGAE is a highly nutritious blend of three species of marine microalgae in a liquid concentrate form. The microalgae used in EPI-ALGAE are grown in closed photo reactors under optimal growing conditions and packaged with a proprietary process that eliminates cell breakage.

EPI-ALGAE offers the following benefits to shrimp hatcheries:

- EPI-ALGAE is an instant algae product always available when it is needed for,
 - Emergency back-up
 - Peak load supplement
 - Live algae replacement
- EPI-ALGAE offers hatchery production flexibility (replace all live algae or just one species)
- EPI-ALGAE stimulate Zoea feeding and reduces the effect of Zoea Syndrome
- EPI-ALGAE offers more complete nutrition than a single alga.
- EPI-ALGAE is pathogen free – grown in bio-secure bioreactors in an inland facility

Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.

Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, estimated construction costs of the new facility, expected improvements in the quality, efficiency and reliability of manufacturing operation. We can provide no assurance that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.

For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com